GSK GSK plc

24.06USD1827.00 GBp · LSE-1.67%Mkt Cap: 96.45B USDP/E: 17.07

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States…

Institutional holders14 on file

Key Statistics

Company
Market Cap96.45B USD
Enterprise Value125.01B USD
Revenue (TTM)44.17B USD
Gross Profit31.14B USD
Net Income (TTM)7.53B USD
Revenue/Share11.00 USD
Last Price24.06 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees66.8K
CountryGB
SectorHealthcare
IndustryDrug Manufacturers - General
ISINGB00BN7SWP63
Valuation
P/E (Trailing)17.07
P/E (Forward)9.75
PEG6.32
EV/EBITDA8.26
EV/Revenue2.83
P/S2.18
P/B3.91
EPS (TTM)1.41 USD
EPS (Forward)2.47 USD
52W Range
22.8517% of range30.05
52W High30.05 USD
52W Low22.85 USD
Profitability
Gross Margin72.40%
Oper. Margin30.54%
EBITDA Margin34.26%
Profit Margin17.50%
ROE34.90%
ROA9.35%
ROIC23.22%
ROCE20.99%
Growth
Revenue Growth4.00%
Earnings Growth-22.80%
Cash Flow & Leverage
Operating CF10.19B USD
CapEx (TTM)3.93B USD
FCF Margin16.56%
FCF Yield7.58%
Net Debt27.44B USD
Net Debt/EBITDA1.81
Net Debt/FCF3.75
Balance Sheet
Debt/Equity1.08
Current Ratio0.86
Quick Ratio0.55
Book Value/Sh6.16 USD
Cash/Share0.97 USD
Dividends
Fwd Div Rate0.0090 USD
Trail. Div Rate0.0091 USD
Div. Yield3.66%
5Y Avg Yield4.09%
Payout Ratio63.61%
Ex-Div DateNov 12, 2026
Pay Date—
Splits
Last Split4:5
Split DateJul 19, 2022
Analyst Consensus
Rating2.6 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)28.28 USD
Upside (mean)+17.5%
Target Range19.16 USD – 39.56 USD
19.16+17.5% to mean39.56
# Analysts21
Ownership
Shares Out.4.01B
Float3.89B
Insiders1.87%
Institutions48.18%
Technical
SMA 5024.34 (-1.2%)
SMA 20025.70 (-6.4%)
Beta0.28
S&P 52W Chg12.08%
Avg Vol (30d)5.67M
Avg Vol (10d)5.18M
Technical Indicators
RSI (14)43.2
MACD5.8740
MACD Signal11.6372
MACD Hist.-5.7631
BB Upper25.70 USD
BB Middle24.73 USD
BB Lower23.76 USD
BB Width7.88%
ATR (14)0.5779 USD
Vol Ratio (20d)0.96x

About GSK (LON: GSK)

›

GSK (LON: GSK) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Drug Manufacturers - General industry, part of the Healthcare sector, and reports about 66,841 employees.

The shares were at 1827.00 GBp on 19 November 2026, roughly unchanged over 52 weeks. Its 52-week range is 1735.50 GBp to 2282.00 GBp: the price is 19.9% below the high and 5.3% above the low.

At a market capitalisation of 73.24B GBP, it trades at 17.1 times trailing earnings and 9.8 times forward earnings. The median trailing P/E of its 19 largest Drug Manufacturers - General peers is 26.0, a discount of 34% for GSK. It pays a dividend yielding 3.66% (it pays out 64% of its earnings), against a median of 2.43% among the dividend payers in that peer group.

GSK reports return on equity of 34.9%, an operating margin of 30.5% and revenue up 4.0% year over year.

Its debt exceeds its cash by 20.84B GBP, a debt-to-equity ratio of 1.08. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 21 analysts cover the stock, with an average rating of Hold; their mean price target of 2147.38 GBp is 17.5% above the current price. The next earnings report is expected on 3 February 2027.